The relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis

Creative Commons License

Kadayifci F. Z., Karadag M.

EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.5, sa.1, ss.1-4, 2018 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/eurjrheum.2017.17287
  • Dergi Adı: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-4
  • Gazi Üniversitesi Adresli: Evet

Özet

Objective: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS).